Screening primary sclerosing cholangitis and biliary dysplasia with endoscopic retrograde cholangiography and brush cytology: risk factors for biliary neoplasia
The DOI matches its Crossref record.
Abstract
Background and study aims Primary sclerosing cholangitis (PSC) is associated with increased risk of biliary dysplasia and cholangiocarcinoma (CCA). The aim of this study was to evaluate the role of early endoscopic retrograde cholangiography (ERC) with systematic brush cytology to identify risk factors associated with biliary neoplasia. Patients and methods Patients who were referred for their first ERC for suspicion of PSC between January 2006 and October 2011 were included in the study. Brush cytology specimens were scored as benign, suspicious, or malignant. End points were CCA, biliary dysplasia, benign histology, or benign disease course for ≥ 2 years. Results PSC was diagnosed in 261 patients (125 men, 136 women), most of whom were asymptomatic (n = 211). Cholangiographic changes were mild in 57.1 %. Men presented with advanced disease more often than women. Brush cytology was benign in 243, suspicious in 16, and malignant in 2 patients. Follow-up completed in 249 patients indicated a benign disease course in 232 patients. Seven patients were diagnosed with CCA and eight had biliary dysplasia in the explanted liver. Thus, 15 patients had biliary neoplasia, and suspicious or malignant brush cytology had been detected in 8 of them at initial brushing. Advanced extrahepatic cholangiographic changes with elevated aminotransferases at diagnosis seemed to be associated with increased risk of biliary neoplasia. Conclusions Even in mostly asymptomatic patients with PSC, 42.9 %…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“data from Finland suggest that ERCP, especially in advanced extrahepatic PSC, may be beneficial for detection of premalignant or malignant lesions regardless of symptoms.131”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [131]
Citations
Cited by
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Chapman, M. H., Thorburn, D., Hirschfield, G. M., Webster, G. G. J., Rushbrook, S. M., Alexander, G., Collier, J., Dyson, J. K., Jones, D. E., Patanwala, I., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317993 · Cited by 284
Aabakken, L., Karlsen, T., Albert, J., Arvanitakis, M., Chazouilleres, O., Dumonceau, J.-M., Färkkilä, M., Fickert, P., Hirschfield, G., Laghi, A., et al. (2017) · Endoscopy · doi:10.1055/s-0043-107029 · Cited by 255
Self-citationSchramm, C., Eaton, J., Ringe, K. I., Venkatesh, S., Yamamura, J., & for the MRI working group of the IPSCSG (2017) · Hepatology · doi:10.1002/hep.29293 · Cited by 147
“The development of such features should prompt additional studies including ERCP with biliary brushings/biopsies.((78-80)) There is neither supporting nor refuting evidence to suggest that CCA screening with any test is associated with improved outcomes or cost-savings.”
BackgroundAabakken, L., Karlsen, T. H., Albert, J., Arvanitakis, M., Chazouilleres, O., Dumonceau, J.-M., Färkkilä, M., Fickert, P., Hirschfield, G. M., Laghi, A., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.013 · Cited by 107
“A complete occlusion cholangiogram should generally be obtained if an ERCP is performed, because it adds little risk to the ERCP, decreases variability, and may reveal that a dominant stricture suspected at MRC is indeed not a stricture [37].”
Self-citationPereira, P., Aho, V., Arola, J., Boyd, S., Jokelainen, K., Paulin, L., Auvinen, P., & Färkkilä, M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182924 · Cited by 96
Self-citationCholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review
Song, J., Li, Y., Bowlus, C. L., Yang, G., Leung, P. S. C., & Gershwin, M. E. (2019) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08764-7 · Cited by 114
Barner-Rasmussen, N., Pukkala, E., Jussila, A., & Färkkilä, M. (2020) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2019.1707277 · Cited by 80
“If the MRCP was compatible with PSC, ERC with BC was performed for an individual risk stratification that is based on bile duct changes (modified ERC-score) [22], bile duct inflammation and on possible biliary dysplasia in BC (Figure 1).”
BackgroundMethodSelf-citationThe Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies
Özdirik, B., Müller, T., Wree, A., Tacke, F., & Sigal, M. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136975 · Cited by 70
Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma
Ilyas, S. I., Eaton, J. E., Yang, J. D., Chandrasekhara, V., & Gores, G. J. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1655775 · Cited by 61
“43,44,53 Indeed, an unpublished subgroup analysis from the aforementioned multifocal polysomy paper revealed that 14% (3/22) of patients with suspicious cytology alone (i.e., lack polysomy or a mass lesion) may have CCA diagnosed after a median follow-up of 1.5 years.”
BackgroundInfluentialVedeld, H. M., Grimsrud, M. M., Andresen, K., Pharo, H. D., von Seth, E., Karlsen, T. H., Honne, H., Paulsen, V., Färkkilä, M. A., Bergquist, A. M., et al. (2021) · Hepatology · doi:10.1002/hep.32125 · Cited by 59
“[31] Other surveillance strategies also exist, including using ERCP and brush cytology as primary surveillance tools.[33,34] Both CA 19- 9[31] and imaging[32] display suboptimal accuracy for CCA detection, although MRI was recently reported to be superior to ultrasound for detection of early- stage CCA in asymptomatic…”
MethodSelf-citationStaging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Burkhart, R. A., & Pawlik, T. M. (2017) · Cancer Control · doi:10.1177/1073274817729235 · Cited by 42
Tenca, A., Mustonen, H., Lind, K., Lantto, E., Kolho, K., Boyd, S., Arola, J., Jokelainen, K., & Färkkilä, M. (2018) · Liver International · doi:10.1111/liv.13899 · Cited by 37
Self-citationBoyd, S., Mustonen, H. K., Tenca, A., Jokelainen, K., Arola, J., & Färkkilä, M. A. (2016) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2016.1250281 · Cited by 34
“The lack of additional advantage of ploidy analysis was also seen in another study among patients with newly diagnosed PSC.[15] Also, the BC samples at the present study with the new collection technique were more representative containing an abundance of cells.”
MethodResultInfluentialSelf-citationEhlken, H., Zenouzi, R., & Schramm, C. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000335 · Cited by 29
Berg, T., Aehling, N., Bruns, T., Welker, M., Weismüller, T. J., Trebicka, J., Tacke, F., Strnad, P., Sterneck, M. R., Settmacher, U., et al. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2255-7246 · Cited by 32
Majeed, A., Castedal, M., Arnelo, U., Söderdahl, G., Bergquist, A. M., & Said, K. (2017) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2017.1385840 · Cited by 26
“fluorescence in situ hybridization (FISH), is used for investigating biliary strictures suspicious for malignancy in patients with PSC [7].”
BackgroundEndoscopic Management of Primary Sclerosing Cholangitis
Barkin, J. A., Levy, C., & Souto, E. O. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0010.5274 · Cited by 23
Diagnosis of cholangiocarcinoma in primary sclerosing cholangitis
Taghavi, S. A., Eshraghian, A., Niknam, R., Sivandzadeh, G. R., & Lankarani, K. B. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1473761 · Cited by 22
Kamp, E. J. C. A., Dinjens, W. N. M., Doukas, M., van Marion, R., Verheij, J., Ponsioen, C. Y., Bruno, M. J., Koerkamp, B. G., Trivedi, P. J., Peppelenbosch, M. P., et al. (2022) · The Journal of Pathology · doi:10.1002/path.5994 · Cited by 24
Boyd, S., Vannas, M. J., Jokelainen, K., Isoniemi, H., Mäkisalo, H., Färkkilä, M. A., & Arola, J. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i33.6147 · Cited by 20
Self-citationVannas, M. J., Boyd, S., Färkkilä, M. A., Arola, J., & Isoniemi, H. (2016) · Liver International · doi:10.1111/liv.13276 · Cited by 16
Self-citationNovel histological scoring for predicting disease outcome in primary sclerosing cholangitis
Sjöblom, N., Boyd, S., Kautiainen, H., Arola, J., & Färkkilä, M. A. (2022) · Histopathology · doi:10.1111/his.14677 · Cited by 16
Self-citationPörner, D., Kaczmarek, D. J., Heling, D., Hausen, A., Mohr, R. U., Hüneburg, R., Matthaei, H., Glowka, T. R., Manekeller, S., Fischer, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-74451-9 · Cited by 17
Sjöblom, N., Boyd, S., Manninen, A., Blom, S., Knuuttila, A., Färkkilä, M. A., & Arola, J. (2022) · Hepatology Research · doi:10.1111/hepr.13867 · Cited by 15
“P‐ALB, g/L, median (IQR) 36 (32, 39) 39 (36, 41)”
Self-citationBoyd, S., Mustamäki, T., Sjöblom, N., Nordin, A. J., Tenca, A., Jokelainen, K., Rantapero, T., Liuksiala, T., Lahtinen, L., Kuopio, T., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000415 · Cited by 12
“…– magnetic resonance cholangiography features suggestive of LGD/HGD. [34] Initially, we performed ploidy analysis using DNA flow cytometry with BC; [19,35] however, as no significant additive value was observed during dysplasia surveillance, [15] we began to use NGS analysis as an ancillary test…”
MethodInfluentialSelf-citationHolm, M., Joenväärä, S., Saraswat, M., Tohmola, T., Saarela, T., Tenca, A., Arola, J., Renkonen, R., & Färkkilä, M. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272810 · Cited by 12
“The findings of ERC were scored according to the Helsinki score (modified Amsterdam score, range 2–16) [15].”
MethodSelf-citationUegWeek 2020 Poster Presentations
de Pierola, L. B. F., Nyssen, O. P., Cosme, Á., Bordin, D. S., Tepeš, B., Aísa, Á. P., Vaira, D., Álvarez, M. C., Fernández, M. C., Lerang, F., et al. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620927345 · Cited by 12
Cholangiocarcinoma Surveillance Recommendations in Patients with Primary Sclerosing Cholangitis
Saca, D., & Flamm, S. L. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.07.010 · Cited by 10
Cancer risk, screening and surveillance in primary sclerosing cholangitis
Chascsa, D. M. H., & Lindor, K. D. (2019) · Minerva Gastroenterologica e Dietologica · doi:10.23736/s1121-421x.19.02586-8 · Cited by 12
Vannas, M. J., Färkkilä, M. A., Sintonen, H., Åberg, F. O., & Isoniemi, H. (2020) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2020.1725106 · Cited by 7
“Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, which usually has minimal or no symptoms if diagnosed at an early stage [1,2].”
BackgroundSelf-citationAutorinnen/Autoren, & Collaborators (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2558-5204 · Cited by 10
Koskensalo, V., Aronen, P., Färkkilä, M. A., Kylänpää, L., Lindström, O. K., Rainio, M., Udd, M., Jokelainen, K., & Tenca, A. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.05.009 · Cited by 5
Self-citationNavigating Neoplasm Risk in Inflammatory Bowel Disease and Primary Sclerosing Cholangitis
Pitoni, D., Buono, A. D., Gabbiadini, R., Ronca, V., Colapietro, F., Pugliese, N., Ribaldone, D. G., Bezzio, C., Lleò, A., & Armuzzi, A. (2025) · Cancers · doi:10.3390/cancers17132165 · Cited by 8
“A higher frequency of metaplasia and dysplasia of cholangiocytes has been observed in patients with PSC-CCA, compared with those with PSC without neoplasia, regardless of the duration of the disease [60,62,63].”
Barner‐Rasmussen, N., Molinaro, A., Mol, B., Ponsioen, C. Y., Bergquist, A. M., Kautiainen, H., & Färkkilä, M. A. (2025) · Endoscopy · doi:10.1055/a-2511-3422 · Cited by 9
Self-citationTenca, A., Kolho, K., Consonni, D., Jokelainen, K., & Färkkilä, M. A. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12583 · Cited by 3
“10,11 The presence of a DS in the perihilar region or extra ‐ hepatic bile ducts is highly suspicious for CC. 10 In a large retrospective multi ‐ centre study including 781 paediatric PSC patients, with a median age of 12 years, symptomatic DS developed in 16% of the patients within 5 years of diagnosis.”
BackgroundMethodInfluentialSelf-citationLieb, K. R., Williams, Z. E., Sayles, H. R., Zaman, M., & Dhir, M. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17292-y · Cited by 4
“…cholangiopancreatography), relevant serum markers (CA 19-9), and close follow-up (to monitor symptoms) are all employed in the treatment of PSC. 13,15,18 Some strictures may need to be more urgently treated endoscopically with dilation or stenting rather than biopsied, causing a necessary delay…”
The changing faces of cholangitis
Lee, S. P., Roberts, J. R., & Kuver, R. (2016) · F1000Research · doi:10.12688/f1000research.8745.1 · Cited by 4
Barner‐Rasmussen, N., Sjöblom, N., Arola, J. T., Boyd, S., Kautiainen, H., & Färkkilä, M. A. (2023) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2023.2233038 · Cited by 3
“In our center, ≥80% of patients were asymptomatic at the time of diagnosis [34].”
BackgroundSelf-citationThylin, M., Färkkilä, M. A., Kautiainen, H., Barner‐Rasmussen, N., Jokelainen, K., Puustinen, L., Boyd, S., Arola, J. T., & Tenca, A. (2024) · Liver International · doi:10.1111/liv.15985 · Cited by 3
“Cytology samples were scored as previously described 16 Variables were presented as the median and interquartile range (IQR) when ordinal and as number and percentage when nominal.”
Self-citationFärkkilä, M. A., Åberg, F. O., Alfthan, H. V., Jokelainen, K., Puustinen, L., Kautiainen, H., & Tenca, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101161 · Cited by 6
“Images were evaluated using the Helsinki score (modi fi ed Amsterdam score); 20 see Fig.”
Self-citationSebode, M., Bantel, H., Baumann, U., Bufler, P., Demir, M., Dold, L., Keitel, V., Klein, R., Kremer, A. E., Jansen, P. L., et al. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2769-2475 · Cited by 2
Färkkilä, M. A., Kautiainen, H., Tenca, A., Jokelainen, K., & Arola, J. T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277084 · Cited by 3
“Brush cytology was collected from extra- and intrahepatic bile ducts, regardless of DS [26] using a brush with a guide wire (RX Cytology Brush, Boston Scientific, MA, USA).”
MethodSelf-citationBreder, S., Villard, C., Eide, E., Wang, B., Engesæter, L. K., Reims, H. M., Hov, J. R., Melum, E., Aabakken, L., Line, P., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101598 · Cited by 2
Koistinen, H. K., Boyd, S., Arola, J., Jokelainen, K., Koistinen, R., Lempiäinen, A., Hotakainen, K., Stenman, U., & Färkkilä, M. A. (2021) · Livers · doi:10.3390/livers1040025 · Cited by 2
“ERC findings were scored according to the Helsinki score [14], modified from the Amsterdam score.”
MethodSelf-citationAre we ready to change our surveillance strategy for primary sclerosing cholangitis patients?
Lemmers, A. (2025) · Endoscopy · doi:10.1055/a-2541-3986
“” follow-up ERCP (from 3months to 5years) then based on multiple factors (e.g. severity of the cholangiogram, Helsinki score [2], need for dilation, degree of biliary inflammation assessed by cytology, biliary calprotectin, and IL-8, and the presence of Are we ready to change our biliary dysplasia…”
Malik, U. E., Ashraf, B., Samuel, S. B., & Hasak, S. (2025) · Clinical gastroenterology · doi:10.1007/978-3-032-07868-1_12
Färkkilä, M. A., Bergquist, A. M., Molinaro, A., Tenca, A., Middelburg, T., Ponsioen, C. Y., & Kautiainen, H. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.05.005
Self-citationFärkkilä, M. A., Arola, J. T., Tenca, A., Jokelainen, K., Boyd, S., & Kautiainen, H. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101967
Self-citationScreening for Biliary Dysplasia Using Brush Cytology in PSC : Prevalence, Risk Factors and Outcomes
Färkkilä, M. A., Boyd, S., Åberg, F. O., Tenca, A., Jokelainen, K., Kautiainen, H., & Arola, J. T. (2026) · Liver International · doi:10.1111/liv.70910
“Neutrophilic inflammation in BC was evaluated semi-quantitatively (0 = neutrophils/epithelial cells < 0.05, 1 = neutrophils/epithelial cells 0.05–0.4, 2 = neutrophils/epithelial cells > 0.4) and likewise for lymphocytes [22].”
InfluentialSelf-citation
Metadata
- Authors
- Boyd, S., Tenca, A., Jokelainen, K., Mustonen, H., Krogerus, L., Arola, J., & Färkkilä, M.
- Affiliations
- University of Helsinki (FI)
- Venue
- Endoscopy
- Publisher
- Georg Thieme Verlag KG
- Published
- 2016-01-25
- Volume
- 48
- Issue
- 05
- Pages
- 432-439
- ISSN
- 0013-726X (ISSN-L)
- 1438-8812
- OpenAlex
- W2290113997
- Cited by
- 50
- References
- 0
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 5 · 2023: 2 · 2022: 6 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 9 · 2016: 3
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endoscopy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Keywords
- primary sclerosing cholangitis, biliary dysplasia, cholangiocarcinoma, brush cytology, endoscopic retrograde cholangiography, transaminases, early detection, asymptomatic patients
- MeSH terms
- Adult, Transaminases, Bile Duct Neoplasms, Bile Ducts, Cholangiopancreatography, Endoscopic Retrograde, Cytodiagnosis, Diagnosis, Differential, Female, Finland, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Cholangitis, Sclerosing, Cholangiocarcinoma, Early Detection of Cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.